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Abstract
SFTS virus (SFTSV) is a novel bunyavirus that causes severe fever with thrombocytopenia syndrome (SFTS), an emerging infectious disease
that occurred in China in recent years, with an average case fatality rate of 10–12%. Intervention in the early clinical stage is the most effective
measure to reduce the mortality rate of disease. To elucidate the natural course of and immune mechanisms associated with the pathogenesis
of SFTSV, 59 laboratory-conﬁrmed SFTS patients in the acute phase, who were hospitalized between October 2010 and September 2011,
were enrolled in this study, and the patients sera were dynamically collected and tested for SFTSV viral RNA load, 34 cytokines or chemokines
and other related laboratory parameters. All clinical diagnostic factors in the acute phase of SFTS were evaluated and assessed. The study
showed that the severity of the disease in 11 (18.6%) patients was associated with abdominal pain (p 0.007; OR = 21.95; 95% CI, 2.32–208.11)
and gingival bleeding (p 0.001; OR = 122.11; 95% CI, 6.41–2328). The IP-10, TNF-a, IL-6, IL-10, granzyme B and HSP70 levels were higher
over the 7–8 days in severe cases, accompanied by altered AST, CK and LDH levels. HSP70 (p 0.012; OR = 8.29; 95% CI, 1.58–43.40) was
independently correlated with the severity of the early acute phase of SFTSV infection. The severity of SFTS can be predicted based on the
presence of symptoms such as abdominal pain and gingival bleeding and on the level of HSP70 in the acute phase of the disease.
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Introduction
Severe fever with thrombocytopenia syndrome (SFTS) is an
emerging infectious disease caused by the SFTS virus, a novel
tick-borne phlebovirus in the family of Bunyaviridae [1] that was
ﬁrst identiﬁed in China in 2010. Up to now, SFTS cases have
been reported in 17 provinces according to the information
system for disease control and prevention, China CDC. SFTS
cases were also identiﬁed in Japan [2] and Korea [3], and
similar new phleboviruses were reported in the US [4] and
India [5]. The SFTS case-fatality rate in China is still 10–16%
[6], and more severe in Japan, reaching 54.5% [3]. However,
currently there are no licensed vaccines or pharmaceutical
options approved for clinical therapy.
The clinical symptoms and signs caused by this new
bunyavirus are non-speciﬁc, including high fever, severe
malaise, nausea, vomiting and diarrhoea, with bleeding tenden-
cies [1,7]. These are abnormalities associated with other viral
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haemorrhagic fevers, including leukopenia, severe thrombocy-
topenia, coagulation abnormalities and elevated liver transam-
inases [7,8]. The natural history and underlying pathogenesis of
SFTS are unknown. Severe cases of SFTS develop multiple
organ dysfunction (MOD) and disseminated intravascular
coagulation (DIC) quickly, and even result in death 7–14 days
after the onset of illness [8]. Cytokine storm, a potentially fatal
immune reaction occurring in the acute phase of several viral
infections, has been widely hypothesized as the main cause of
morbidity and mortality in diseases such as Ebola haemorrhagic
fever [9,10], Dengue haemorrhagic fever [11], Crimean-Congo
haemorrhagic fever (CCHF) [12,13] and Rift Valley fever (RVF)
[14]. Recent data suggest that the physiological balance of
multiple proinﬂammatory cytokines was substantially changed
in severe or fatal SFTSV infections [8,15]. The cytokine-med-
iated inﬂammatory response probably plays an important role
in the disease progression. In order to identify potential
immune mediators contributing to disease severity, we
explored the symptoms and biomarkers associated with the
acute phase of SFTSV infections.
Methods
Patients and samples
In this prospective study, we included 59 patients who were
admitted to Yantai Infectious Diseases Hospital or Laizhou
Hospital in Shandong Province, and Guangshan Hospital,
Shangcheng Hospital or Xinyang Center Hospital in Henan
Province from October 2010 to September 2011. Patients
presented with acute onset of high fever (≥37.5°C), throm-
bocytopenia (<100 9 109/L) and blood SFTSV conﬁrmed by
reverse-transcriptase polymerase chain reaction (RT-PCR) at
admission. The Diagnostic Kit for the Novel Bunyavirus Virus
RNA (PCR-Fluorescence Probing) was from Beijing SinoMD-
gene Technology CO. Ltd (Beijing, China) (SFDA Registration
No 3400073). According to the severe and non-severe SFTSV
infection criteria [15], 11 severe cases and 48 non-severe cases
were enrolled in this study. Admission blood samples were
used for detection of the SFTSV viral load and identiﬁcation of
34 different cytokines or chemokines and clinical laboratory
markers.
Dynamic collection of sera samples
Series of blood samples were collected from 12 out of 59
diagnosed SFTS patients at least two times per patient from
the time of hospital admission. Admission blood samples were
used for detection of viral load, biological parameters, which
were acquired with automated analytical instruments, and for
identiﬁcation of 34 different cytokines or chemokines and
clinical laboratory markers. The results of dynamic serum
analyses were presented according to the days after the onset
of illness, which is useful when observing the entire course of
the disease.
Real-time RT-PCR for SFTS viral RNA assay
To detect the SFTS viral RNA loads in SFTS patients in the
acute phase, viral RNA was extracted from collected serum
samples by using the QIAamp Viral RNA kit (Qiagen, Hilden,
Germany) following the manufacturer’s instructions. The viral
detections were further performed by using a commercially
available quantitative real-time PCR diagnostic kit (DAAN gen
Bio Lid, Guang zhou, China, SFDA Registration No 3401666),
which was based on the detection of the SFTS viral S genomic
segment, according to the manufacturer’s instructions. The
cut-off cycle threshold (Ct) value for a positive sample was set
at 35 cycles [16].
Clinical laboratory analysis and multiplex assays
A large multiplex assay was used to determine the concen-
tration of 34 different serum proteins: interleukin IL-1 a, IL-1 b,
IL-2, IL-4, IL-5, IL-6, IL-10, IL-15, IL-17, IL-12p70 and sIL-2RA;
granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon-a2 (IFN-a2), interferon-c (IFN-c) and tumor necro-
sis factor-a (TNF-a); chemokines including macrophage inﬂam-
matory protein (MIP-1a, MIP-1-b), IP-10, RANTES and GRO,
IL-8; and other proteins including TGF-ba, PDGF-BB, sCD40L,
VEGF, MIF, sICAM-1, sFasL, sFas, sVCAM-1, tPAI-1, gran-
zyme-B, HSP70 and MMP-8. Cytokines and protein assays
were performed in duplicate, according to the manufacturer’s
instructions (Millipore-Milliplex MAP kit, Merck Millipore,
Billerica, MA, USA) and analyzed on a Luminex 200 IS platform
(Luminex, Austin, TX, USA).
Statistical analysis
Results were analysed using the statistical software package
SPSS 16.0 (SPSS, an IBM Company, Armonk, NY, USA).
Continuous variables were analysed after logarithmic trans-
formation. Statistical analyses were performed using the
Pearson v2 or Fisher’s exact test in tables to test relationships
between clinical presentation and severity of the diseases.
Comparison of clinical parameters between severe and
non-severe cases was carried out by the unpaired t-test or
Mann–Whitney U-test (for continuous variables). The corre-
lation between variables was assessed using the Pearson test.
Risk factors in severe patients were analysed by binary logistic
regression. p values <0.05 were considered statistically signif-
icant. The statistical graphs were performed by Graph Pad
Prism 5.00 (GraphPad Software, San Diego, CA, USA) and
SPSS 16.0.
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Ethics statement
All patients gave written consent to participation in our study.
To ensure conﬁdentiality, anonymity and informed consents,
the investigation adopted international guidelines and was
reviewed by the Ethics Committee of China CDC.
Results
Clinical demographics of acute SFTSV infection
Fifty-nine patients hospitalized with laboratory-conﬁrmed
SFTSV infection were enrolled in this study. The median
interval between the onset of illness and extraction of serum
samples at admission was 6 days (range, 1–13 days). The
median age of the patients was 61 years (range, 23–82 years),
with a female to male ratio of 30:29. Eleven cases were severe
(18.6%), 10 patients had a history of conﬁrmed tick bite (16.9%),
and seven patients (11.9%) died. Dynamic specimen collection
(more than twice per patient) was performed in 12 of the 59
patients enrolled. Fatigue, lack of appetite, dizziness, myalgia,
nausea, vomiting, headache, apathia and abdominal tenderness
were the most frequent clinical complaints. The incidence of
diarrhoea, abdominal pain, abdominal tenderness, restlessness,
muscular tremor, gingival bleeding, ecchymosis, hemorrhea and
melena was higher in severe cases compared with non-severe
cases (Table 1). Regression analysis suggested that the symp-
toms of abdominal pain, diarrhoea, abdominal tenderness,
gingival bleeding, melena, ecchymosis, hemorrhea, infrequent
pulse, restlessnes and muscular tremor were risk factors for
severe infection. Further analysis suggested that abdominal pain
(p 0.007; OR = 21.95; 95% CI, 2.32–208.11) and gingival
bleeding (p 0.001; OR = 122.11; 95% CI, 6.41–2328) were
independent risk factors for severe SFTS cases (Table 2).
Clinical laboratory parameters in the acute phase of SFTSV
infection
To estimate the natural course of organ injury, the clinical
laboratory parameters in 59 SFTS patients, including 11 severe
cases and 48 non-severe cases, were analyzed and laboratory
parameters at admission consistent with individual patients’
samples were plotted against the day since onset of illness. We
found that severe SFTS cases were observed at a signiﬁcantly
higher age compared with non-severe cases (median 66.5 vs.
59.5 years; p 0.005) (Table 3). Laboratory analysis showed
that the platelet (PLT) and white blood cell (WBC) levels in the
peripheral blood in both severe and non-severe cases were
lower than normal standards (Table 3, Fig. 1); there was no
signiﬁcant difference between the severe and non-severe
cases. However, the SFTSV viral RNA load in patients’ blood
ranged from 0.51 9 102 to 6.88 9 104 copies/mL and the
viral loads were signiﬁcantly higher in severe cases (average
RNA viral load was 1.91 9 103 copies/mL) compared with
non-severe cases (average RNA viral load was
0.75 9 102 copies/mL) (p 0.021, Table 3). For the organ
enzymes, asparate aminotransferase (AST) (p 0.003), creati-
nine phosphokinase (CK) (p 0.001) and lactic acid dehydro-
genase (LDH) (p 0.005) were signiﬁcantly higher in severe
cases compared with non-severe cases, while alanine amino-
TABLE 1. The symptoms or signs in patients in the acute
phase of SFTS
Symptoms or signs
Non-severe
(n = 48)
No. (%)
Severe
(n = 11)
No. (%) p-Value
General symptoms
Fever 48 (100) 11 (100)
Fatigue 47 (97.9) 11 (100) 0.814
Myalgia 29 (60.4) 6 (54.5) 0.745
Arthralgia 8 (16.7) 0 (0.0) 0.330
Infrequent pulse 1 (2.1) 2 (18.2) 0.086
Gastrointestinal signs
Lack of appetite 41 (85.4) 11 (100) 0.328
Nausea 27 (56.2) 7 (63.6) 0.745
Diarrhoea 7 (14.6) 7 (63.6) 0.002
Abdominal pain 9 (18.8) 7 (63.6) 0.006
Abdominal tenderness 8 (16.7) 6 (54.5) 0.015
Vomiting 24 (50.0) 7 (63.6) 0.513
Borborygmus 0 (0.0) 1 (9.1) 0.186
Abdominal distension 1 (2.1) 1 (9.1) 0.341
Rebound tenderness 1 (2.1) 0 (0.0) 1.0
CNS manifestations
Dizziness 26 (54.2) 8 (72.7) 0.325
Headache 16 (33.3) 5 (54.5) 0.300
Apathia 15 (31.2) 6 (54.5) 0.175
Muscular tremor 4 (8.3) 4 (36.4) 0.033
Restlessness 0 (0.0) 2 (18.2) 0.032
Lethargy 2 (4.2) 0 (0.0) 1.000
Meningismus 1 (2.1) 0 (0.0) 0.814
Hemorrhagic signs
Gingival bleeding 1 (2.1) 5 (45.5) 0.001
Melena 0 (0.0) 2 (18.2) 0.032
Ecchymosis 4 (8.3) 4 (36.4) 0.033
Hemorrhea 1 (2.1) 3 (27.3) 0.018
Lymphadenopathy
Lymphadenectasis 9 (18.8) 2 (18.2) 0.536
Subinguinal lymphadenopathy 8 (16.7) 2 (18.2) 0.932
Tenderness of lymph nodes 7 (14.6) 2 (18.2) 0.536
The Pearson v2 test or Fisher exact test was used to compare qualitative variables.
Statistical analyses were performed using SPSS v. 16.0.
p <0.05 was considered statistically signiﬁcant.
TABLE 2. The univariate and multivariate risk factors for
the severity of the acute phase in SFTS patients
Symptoms and signs pa pb OR 95% CI
Abdominal pain 0.003 0.007 21.95 (2.32 208.11)
Diarrhoea 0.001
Abdominal tenderness 0.008
Gingival bleeding 0.000 0.001 122.11 (6.41 2328)
Melena 0.003
Ecchymosis 0.014
Infrequent pulse 0.028
Hemorrhea 0.003
Restlessness 0.003
Muscular tremor 0.014
Univariate and multivariate risk factors were analysed by binary logistic regression
using SPSS v.16.0.
p <0.05 was considered statistically signiﬁcant.
aStep 0, variables not in the equation.
bStep 8, Block 1: method = backward stepwise (Wald).
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transeferase (ALT) levels tended to rise in severe cases
(Table 3, Fig. 1). The ALT, AST and LDH levels reached a peak
by the 10th day in severe cases, and then gradually declined
(Fig. 1). Viral RNA levels appeared to gradually decline 6–
10 days after illness onset in severe cases. The viral loads in
serially obtained blood specimens from 12 patients were also
included for accurate estimation (Fig. S1).
Correlations of clinical laboratory parameters with altered
cytokines
In order to determine the production trend of the overall
cytokines or chemokines, we analysed 34 cytokines or chemo-
kines in 59 cases of the acute phase of SFTSV infection and 30
healthy controls with Luminex mulitiplex assays. The results
showed that levels of GM-CSF, IP-10, MIP-1a, TNF-a, VEGF,
sVCAM-1, sICAM-1, granzyme B, IFN-a2, IFN-c, IL-2, IL-5, IL-8
and HSP70 were higher in SFTSV patients compared with
healthy controls (Fig. 2b). However, plasminogen activator
inhibitor (tPAI-1), PDGF-BB and GROwere lower in the SFTSV
patients than healthy controls (Fig. 2a). Further, the levels of
IL-10, IL-6, MIP-1a, IP-10, IL-8, IL-15, TNF-a, granzyme B, IFN-c
and HSP70 were signiﬁcantly higher in severe cases compared
with non-severe cases (Fig. 3). As for the days since illness
onset, the levels of MIP-1a, IFN-c and IL-15 in severe cases were
higher than in non-severe cases in the ﬁrst 6 days of illness,
while IL-6, TNF-a, granzyme B, IP-10 and HSP70 kept a higher
tendency until the eighth day (Fig. 4). The levels of IL-10, IL-6,
IFN-c, TNF-a, granzyme B and HSP70 were relatively stable in
non-severe cases, but changed signiﬁcantly in severe cases with
the progress of the illness (Fig. 4). The dynamic analysis
indicated that the up-regulation of the proinﬂammatory cyto-
kines was associated with the severity of SFTS.
TABLE 3. Clinical laboratory parameters in patients in the
acute phase of SFTS
Clinical parameters
Non-severe
(n = 48)
Mean (range)
Severe (n = 11)
Mean (range) p-Value
Illness onset (days) 6 (1–13) 6.5 (4–11) 0.716
Age (years) 59.5 (23–82) 66.5 (59–79) 0.005
Lg virus load (copies/mL) 1.88 (1.71–4.39) 3.28 (2.28–4.84) 0.021
White blood
cells (9 109/L)
3.295 (0.9–16.45) 2.2 (1.6–4.03) 0.271
Neutrophils (9 109/L) 1.60 (0.50–14.54) 1.31 (0.70–3.35) 0.677
Platelets (9 109/L) 64 (11–197) 46.5 (14–95) 0.122
Alanine
aminotransferase(U/LL)
57.1 (9–398.4) 133 (17–455) 0.067
Aspartate
aminotransferase(U/L)
89 (15–1129) 495.5 (78–1073) 0.003
Creatine kinase (U/L) 152 (11.6–3260) 1140 (189–9800) 0.001
Lactate
dehydrogenase (U/L)
289 (117–1343) 798.5 (372–1436) 0.005
Serum sodium (mM)a 138.28  4.11 136.00  5.22 0.114
aSerum sodium (mM) was normal distribution, F = 1.777. Statistical analyses were
performed using an independent samples t-test. The other clinical parameters
were performed by non-parameter Mann–Whitney U-test.
p <0.05 was considered statistically signiﬁcant.
FIG. 1. Dynamic proﬁle of laboratory parameters in 59 patients with acute SFTS (11 severe patients and 48 non-severe cases), every other day,
based on days after the onset of illness. Lines indicate the mean values of the study groups. The red lines show the mean level of each parameter in
severe cases and the black lines indicate the mean level of each parameter in non-severe cases on different days of illness.
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The statistical correlations between viral load and cytokines
suggested that higher levels of circulating virus in SFTS patients
induced higher levels of HSP70, IFN-c, IL-15, sFasl, sIL-2RA and
IFN-a2 (Table 4). The PLT level tended to be lower when the
cytokine sCD40L and PDGF-BB levels decreased or IL-10,
sIL-2RA and IP-10 levels increased. The serum ALT and AST
levels were positively correlated with the cluster of cytokines
or proteins including IL-10, sIL-2RA, HSP70, IP-10, IL-4, IFN-c
and tPAI-1, while the AST level was also positively correlated
with the cytokine IL-15. The serum CK level was positively
correlated with levels of IL-10, sIL-2RA, HSP70, IP-10 and
IL-15. The LDH level was positively correlated with IL-10,
sIL-2RA, HSP70, IP-10, IL-4, IFN-c and IL-15 levels. In contrast,
negative correlations existed between LDH and the cytokines
sFasl or sCD40L (Table 4).
Biomarkers predicting severity in the early acute phase of
SFTSV infection
Based on the 34 different cytokines correlating with AST, CK
and LDH levels in 59 patients, we deﬁned the biomarker levels
<25% as Grade 1, those ranging from 25% to 50% as Grade 2,
those ranging from 50% to 75% as Grade 3, and biomarker
levels exceeding 75% as Grade 4 infection. The phase of illness
within 7 days of symptom onset was deﬁned as the early acute
phase of infection, which was previously reported as the fever
stage of SFTSV infection, involving 38 patients. Univariate risk
factor analysis revealed that the levels of GM-CSF, IL-6, TNF-a,
granzyme-B, HSP70, IL-8, MIP-1a, AST, CK and LDH were
associated with severity in the early acute phase of SFTS
patients (Table 5). Further analysis demonstrated that HSP70
was an independent risk factor for severity in the early acute
(a) (b)
FIG. 2. Comparison of cytokine production in the acute phase of SFTS cases and healthy controls. Cytokines in cluster 1 (a) and cluster 2 (b) were
detected in the acute-phase serum samples from SFTS patients and healthy donors by multiplex-microbead immunoassays. The cytokine levels were
compared between the 59 patients with the acute phase of SFTS and 30 healthy donors. Each dot shows the cytokine concentration in an individual.
Horizontal bars indicate the respective group median. *p <0.05, **p <0.005, ***p <0.001. Abbreviations: GM-CSF, granulocyte colony-stimulating
factor; IL, interleukin; tPAI-1, plasminogen activator inhibitor-1; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, soluble intercellular
adhesion molecule-1; IP, interferon-c inducible protein-10; MCP, monocyte chemotactic protein; PDGF, platelet-derived growth factor.
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phase of SFTS patients (p 0.012; OR = 8.29; 95% CI, 1.58–
43.40).
Discussion
This study systemically investigates the differences between
the severe and non-severe cases on the clinical symptoms,
laboratory parameters and cytokines, chemokines and HSP70
proﬁle during acute phase of SFTS disease. Notably, we
identiﬁed key clinical symptoms and functional serum proteins
related to the severity of outcomes. In addition to fever,
other symptoms and signs include fatigue, lack of appetite,
dizziness, myalgia, nausea, vomiting, headache and apathy,
similar to previous studies of SFTSV infection [1,7]. Severe
cases manifested a higher incidence of symptoms and signs,
including gastrointestinal haemorrhagic signs and neurological
symptoms. Abdominal pain and gingival bleeding suggested
progression of the infection. The natural history of SFTS
encompasses three distinct stages: fever, MOD and conva-
lescence. The fever stage persists for c. 7 days, is exacerbated
within 7–13 days after onset of illness, turning into the MOD
stage [7].
In our study, the viral load declined gradually in patients
after 6–10 days of illness, accompanied by reduced levels of
cytokines and viral RNA (Figs S1 and S2). The high level of viral
load was not only associated with fatal outcome [7,8,17], but
was a risk factor for human-to-human transmission [18–21].
Remarkably, our study showed a high viral load in severe cases,
which suggested that high levels of viral replication were
associated with pathogenesis. Viral factors target the endo-
thelium directly or indirectly. The virus-mediated and
host-derived soluble factors cause endothelial activation and
dysfunction indirectly [15,22] Serum viral load was shown to
correlate with the production of multiple peripheral cytokines
in SFTS. In this study involving the acute phase of SFTS, the
viral RNA loads declined, accompanied by decreased levels of
sIL-2RA, HSP70, IL-15, sFasl, IFN-c and IFN-a2, suggesting that
the cluster of cytokines and protein HSP70 regulated the virus
in the acute phase. IL-10, sIL-2RA, HSP70 and IP-10 were
found to be correlated with the clinical parameters including
ALT, AST, CK and LDH, which indicated impairment in some
FIG. 3. The cytokine levels were compared between the 48 non-severe cases and 11 severe cases in the acute phase of SFTSV infection. Each dot
shows the cytokine concentration in an individual. Horizontal bars indicate the respective group median. *p <0.05, **p <0.005, ***p <0.001.
Abbreviations: MCP, monocyte chemotactic protein; HSP, heat shock protein.
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targeted organs or tissues. The results suggested that the
abnormal production of cytokines and proteins during the
acute phase of SFTSV infection was induced by active viral
replication, partly explaining organ dysfunction [8].
In several clinical studies of haemorrhagic fever, cytokine
storm was shown to be associated with disease severity. In this
study, the levels of cytokines tPAI-1, PDGF-BB and GRO were
lower in the acute phase of SFTSV infection than in healthy
FIG. 4. Dynamic proﬁle of cytokines in 59 patients with acute phase SFTS (11 severe patients and 48 non-severe cases) every other day based on
days after the onset of illness. Brown boxes indicate severe patients and blue boxes indicate non-severe cases. Bars indicate the values of the study
groups. The red lines show the mean level of each cytokine in the severe cases on different days of illness, while the black lines represent the
non-severe cases.
TABLE 4. The correlations between the clinical laboratory parameters and the cytokine levels in patients in the acute phase of SFTS
IL-10 sIL-2RA HSP70 IP-10 IL-15 IL-4 IFN-c tPAI-1 sFasl sCD40L PDGF-BB IFN-a2
Virus load
rp 0.340 0.475 0.342 0.503 0.303 0.337
p NS 0.008 0.000 NS 0.008 NS 0.000 NS 0.020 NS NS 0.007
Platelet count
rp 0.31 0.35 0.28 0.619 0.373
p 0.016 0.006 NS 0.030 NS NS NS NS NS 0.000 0.004 NS
Alanine aminotransferase
rp 0.418 0.290 0.281 0.351 0.428 0.315 0.351
p 0.001 0.029 0.034 0.007 NS 0.001 0.017 0.007 NS NS NS NS
Aspartate aminotransferase
rp 0.293 0.494 0.522 0.535 0.408 0.442 0.387 0.425
p 0.031 0.000 0.000 0.000 0.002 0.001 0.003 0.001 NS NS NS NS
Creatine kinase
rp 0.561 0.339 0.293 0.278 0.399
p 0.000 0.012 0.032 0.042 0.003 NS NS NS NS NS NS NS
Lactate dehydrogenase
rp 0.561 0.591 0.489 0.513 0.302 0.346 0.278 0.355 0.398
p 0.000 0.000 0.000 0.000 0.027 0.010 0.042 NS 0.009 0.003 NS NS
rp, Pearson correlation; NS, no statistical signiﬁcance.
p <0.05 was considered statistically signiﬁcant.
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controls. tPAI-1 is the primary physiological inhibitor of
tissue-type plasminogen activator and urokinase-like plasmin-
ogen activator [23]. The low level of tPAI-1 might be one of
the factors in the pathogenesis of haemorrhage. Low serum
levels of PDGF-BB in SFTS might be related to the decrease in
circulating platelets [24]. The level of the proinﬂammatory
cytokine GRO was lower in fatal than in non-fatal cases of Rift
Valley fever [14]. Additionally, the levels of cytokines or
chemokines IL-6, IL-8, IP-10, MIP-1a, TNF-a, IL-10, IL-15,
granzyme B and IFN-c as well as HSP70 were higher in severe
cases than non-severe cases. Similar innate immune responses
were also reported in other severe cases of bunyavirus
infections such as fatal Rift Valley fever (RVF) disease [14],
Crimean-Congo haemorrhagic fever (CCHF) [12,13] and
haemorrhagic fever with renal syndrome (HFRS) [25,26].
From dynamic changes of cytokines and HSP70 in the acute
phase of SFTS patients, we found that HSP70 and the cluster of
cytokines including TNF-a, IL-6, granzyme B and IP-10 were
sustained at a relatively higher level in the 7–8 days after illness
onset in severe cases compared with non-severe cases. These
cytokines as well as HSP70 might be indicators of SFTS
severity. The levels of IP-10, IL-10 and HSP70 were positively
correlated with the ALT, AST, CK and LDH levels in the
serum. Therefore, we postulated that the elevation of IP-10,
TNF-a, IL-6, IL-10, granzyme B and HSP70 served important
roles in the pathology of liver, heart or skeletal muscle injury in
the acute phase of SFTS.
Early screening and intervention strategies in severe cases
of SFTS effectively reduce the mortality of the disease [7]. In
this study, we found that the proteins GM-CSF, IL-6, TNF-a,
granzyme B, HSP70, IL-8 and MIP1-a were correlated with
the severity of the early acute phase of SFTS (limited to
7 days after illness onset). We found that HSP70 was an
independent biomarker associated with the severity of the
early acute phase of SFTS. HSP70 plays an important role not
only in virus entry but also in post-entry, which located on
the surface of peripheral monocytes/macrophages. The func-
tion of HSP70 in viral disease was previously reported in the
dengue virus; it was part of the dengue virus receptor
complex in monotypic expression of cells binding E protein
and mediating viral internalization [27]; HSP70 was also found
to be associated with membrane microdomains (lipid rafts),
mediating dengue virus entry [28]. The relationship between
HSP70 and SFTSV remains to be further investigated in the
future.
In summary, the unique symptoms and signs, especially in
the acute phase of SFTS, are indicative of severe and
progressive infection and may be important in evaluating the
severity of the disease. Multiple cytokines triggered during the
early acute phase of SFTSV infection were associated with
disease severity. The unique protein patterns identiﬁed in this
study, especially HSP70, serve as early markers to evaluate
disease severity and encourage prompt intervention in the
early acute phase of SFTS.
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TABLE 5. The univariate and multivariate risk factors for
the severity of the early acute phase of SFTS (limited to
7 days after onset)
Risk factors Score pa pb OR 95% CI
GMCSF 4.888 0.027
IL-6 6.30 0.012
TNF-a 3.844 0.050
Grazyme-B 5.349 0.021
HSP70 11.551 0.001 0.012 8.29 (1.58 43.40)
IL-8 6.153 0.013
MIP1-a 4.196 0.041
AST 7.451 0.006
CK 7.731 0.005
LDH 4.754 0.029
Univariate and multivariate risk factors were analysed by binary logistic regression
using SPSS v. 16.0.
p <0.05 was considered statistically signiﬁcant.
aStep 0, variables not in the equation.
bStep 10, Block 1: method = backward stepwise (Wald).
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